Elafin is a biomarker of graft-versus-host disease of the skin

Science Translational Medicine

Volumn 2, Issue 13, 2010, Pages

  Paczesny, Sophie ^a   Braun, Thomas M ^b   Levine, John E ^a   Hogan, Jason ^c   Crawford, Jeffrey ^a   Coffing, Bryan ^a   Olsen, Stephen ^a   Choi, Sung W ^a   Wang, Hong ^c   Faca, Vitor ^c   Pitteri, Sharon ^c   Zhang, Qing ^c   Chin, Alice ^c   Kitko, Carrie ^a   Mineishi, Shin ^a   Yanik, Gregory ^a   Peres, Edward ^a   Hanauer, David ^a   Wang, Ying ^a   Reddy, Pavan ^a   Hanash, Samir ^c   Ferrara, James L M ^a   more..

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ELAFIN;

ADOLESCENT; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHILD; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; RISK FACTOR; SKIN BIOPSY; SKIN DISEASE;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; ELAFIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; GRAFT VS HOST DISEASE; HUMANS; INFANT; INFANT, NEWBORN; MIDDLE AGED; PROGNOSIS; SKIN;

EID: 77952962428     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3000406     Document Type: Article

References (37)

1. G. B. Vogelsang, L. Lee, D. M. Bensen-Kennedy, Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu. Rev. Med. 54, 29-52 (2003).
2. J. L. Ferrara, J. E. Levine, P. Reddy, E. Holler, Graft-versus-host disease. Lancet 373, 1550-1561 (2009).
3. J. H. Antin, H. J. Deeg, Clinical spectrum and pathophysiology of acute graft-vs.-host disease, in Graft-vs.-Host Disease, J. L. M. Ferrara, K. R. Cooke, H. J. Deeg, Eds. (Marcel Dekker, New York, 2005), pp. 369-381.
4. D. Przepiorka, D. Weisdorf, P. Martin, H. G. Klingemann, P. Beatty, J. Hows, E. D. Thomas, 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 15, 825-828 (1995).
5. C. Cutler, J. H. Antin, Manifestations and treatment of acute graft-versus-host disease, in Thomas' Hematopoietic Cell Transplantation, F. Appelbaum, S. J. Forman, R. S. Negrin, K.G. Blume, Eds. Blackwell, Oxford, 2009), pp. 1287-1303.
6. M. T. Van Lint, G. Milone, S. Leotta, C. Uderzo, R. Scimè, S. Dallorso, A. Locasciulli, S. Guidi, N. Mordini, S. Sica, L. Cudillo, F. Fagioli, C. Selleri, B. Bruno, W. Arcese, A. Bacigalupo, Treatment of acute graft-versus-host disease with prednisolone: Significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood 107, 4177-4181 (2006).
7. H. J. Deeg, How I treat refractory acute GVHD. Blood 109, 4119-4126 (2007).
8. S. Paczesny, O. I. Krijanovski, T. M. Braun, S. W. Choi, S. G. Clouthier, R. Kuick, D. E. Misek, K. R. Cooke, C. L. Kitko, A. Weyand, D. Bickley, D. Jones, J. Whitfield, P. Reddy, J. E. Levine, S. M. Hanash, J. L. Ferrara, A biomarker panel for acute graft-versus-host disease. Blood 113, 273-278 (2009).
9. R. Pfundt, M. Wingens, M. Bergers, M. Zweers, M. Frenken, J. Schalkwijk, TNF-α and serum induce SKALP/elafin gene expression in human keratinocytes by a p38 MAP kinase-dependent pathway. Arch. Dermatol. Res. 292, 180-187 (2000).
10. V. Faca, S. J. Pitteri, L. Newcomb, V. Glukhova, D. Phanstiel, A. Krasnoselsky, Q. Zhang, J. Struthers, H. Wang, J. Eng, M. Fitzgibbon, M. McIntosh, S. Hanash, Contribution of protein fractionation to depth of analysis of the serum and plasma proteomes. J. Proteome Res. 6, 3558-3565 (2007).
11. V. Faca, M. Coram, D. Phanstiel, V. Glukhova, Q. Zhang, M. Fitzgibbon, M. McIntosh, S. Hanash, Quantitative analysis of acrylamide labeled serum proteins by LC-MS/MS. J. Proteome Res. 5, 2009-2018 (2006).
12. T. Kaiser, H. Kamal, A. Rank, H. J. Kolb, E. Holler, A. Ganser, B. Hertenstein, H. Mischak, E. M. Weissinger, Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. Blood 104, 340-349 (2004).
13. R. Srinivasan, J. Daniels, V. Fusaro, A. Lundqvist, J. K. Killian, D. Geho, M. Quezado, D. Kleiner, S. Rucker, V. Espina, G. Whiteley, L. Liotta, E. Petricoin, S. Pittaluga, B. Hitt, A. J. Barrett, K. Rosenblatt, R. W. Childs, Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis. Exp. Hematol. 34, 796-801 (2006).
14. E. M. Weissinger, E. Schiffer, B. Hertenstein, J. L. Ferrara, E. Holler, M. Stadler, H. J. Kolb, A. Zander, P. Zürbig, M. Kellmann, A. Ganser, Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 109, 5511-5519 (2007). (Pubitemid 46890577)
15. J. A. Alkemade, H. O. Molhuizen, M. Ponec, J. A. Kempenaar, P. L. Zeeuwen, G. J. de Jongh, I. M. van Vlijmen-Willems, P. E. van Erp, P. C. van de Kerkhof, J. Schalkwijk, SKALP/elafin is an inducible proteinase inhibitor in human epidermal keratinocytes. J. Cell Sci. 107 (Pt 8), 2335-2342 (1994).
16. K. Nonomura, K. Yamanishi, H. Yasuno, K. Nara, S. Hirose, Up-regulation of elafin/SKALP gene expression in psoriatic epidermis. J. Invest. Dermatol. 103, 88-91 (1994).
17. O. Wiedow, J. M. Schröder, H. Gregory, J. A. Young, E. Christophers, Elafin: An elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J. Biol. Chem. 265, 14791-14795 (1990).
18. S. E. Williams, T. I. Brown, A. Roghanian, J. M. Sallenave, SLPI and elafin: One glove, many fingers. Clin. Sci. (Lond.) 110, 21-35 (2006).
19. J. W. McMichael, A. Roghanian, L. Jiang, R. Ramage, J. M. Sallenave, The antimicrobial antiproteinase elafin binds to lipopolysaccharide and modulates macrophage responses. Am. J. Respir. Cell Mol. Biol. 32, 443-452 (2005).
20. J. M. Sallenave, G. A. Cunningham, R. M. James, G. McLachlan, C. Haslett, Regulation of pulmonary and systemic bacterial lipopolysaccharide responses in transgenic mice expressing human elafin. Infect. Immun. 71, 3766-3774 (2003).
21. A. Roghanian, S. E. Williams, T. A. Sheldrake, T. I. Brown, K. Oberheim, Z. Xing, S. E. Howie, J. M. Sallenave, The antimicrobial/elastase inhibitor elafin regulates lung dendritic cells and adaptive immunity. Am. J. Respir. Cell Mol. Biol. 34, 634-642 (2006).
22. J. K. Kolls, P. B. McCray Jr., Y. R. Chan, Cytokine-mediated regulation of antimicrobial proteins. Nat. Rev. Immunol. 8, 829-835 (2008).
23. E. Vachon, Y. Bourbonnais, C. D. Bingle, S. J. Rowe, M. F. Janelle, G. M. Tremblay, Anti-inflammatory effect of pre-elafin in lipopolysaccharide-induced acute lung inflammation. Biol. Chem. 383, 1249-1256 (2002).
24. B. Cowan, O. Baron, J. Crack, C. Coulber, G. J. Wilson, M. Rabinovitch, Elafin, a serine elastase inhibitor, attenuates post-cardiac transplant coronary arteriopathy and reduces myocardial necrosis in rabbits after heterotopic cardiac transplantation. J. Clin. Invest. 97, 2452-2468 (1996).
25. P. A. Rowlings, D. Przepiorka, J. P. Klein, R. P. Gale, J. R. Passweg, P. J. Henslee-Downey, J. Y. Cahn, S. Calderwood, A. Gratwohl, G. Socié, M. M. Abecasis, K. A. Sobocinski, M. J. Zhang, M. M. Horowitz, IBMTR Severity Index for grading acute graft-versus-host disease: Retrospective comparison with Glucksberg grade. Brit. J. Haematol. 97, 855-864 (1997).
26. J. Y. Cahn, J. P. Klein, S. J. Lee, N. Milpied, D. Blaise, J. H. Antin, V. Leblond, N. Ifrah, J. P. Jouet, F. Loberiza, O. Ringden, A. J. Barrett, M. M. Horowitz, G. Socié; Société Française de Greffe de Moëlle et Thérapie Cellulaire; Dana Farber Cancer Institute; International Bone Marrow Transplant Registry, Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: A joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood 106, 1495-1500 (2005).
27. Z. Wang, F. Chen, R. Zhai, L. Zhang, L. Su, X. Lin, T. Thompson, D. C. Christiani, Plasma neutrophil elastase and elafin imbalance is associated with acute respiratory distress syndrome (ARDS) development. PLoS One 4, e4380 (2009).
28. H. A. Alkemade, G. J. de Jongh, W. P. Arnold, P. C. van de Kerkhof, J. Schalkwijk, Levels of skin-derived antileukoproteinase (SKALP)/elafin in serum correlate with disease activity during treatment of severe psoriasis with cyclosporin A. J. Invest. Dermatol. 104, 189-193 (1995).
29. L. Cragg, B. R. Blazar, T. Defor, N. Kolatker, W. Miller, J. Kersey, M. Ramsay, P. McGlave, A. Filipovich, D. Weisdorf, A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol. Blood Marrow Transplant. 6, 441-447 (2000).
30. M. L. MacMillan, D.J. Weisdorf, J. E. Wagner, T. E. DeFor, L. J. Burns, N. K. Ramsay, S. M. Davies, B. R. Blazar, Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: Comparison of grading systems. Biol. Blood Marrow Transplant. 8, 387-394 (2002).
31. D. Weisdorf, R. Haake, B. Blazar, W. Miller, P. McGlave, N. Ramsay, J. Kersey, A. Filipovich, Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: An analysis of clinical risk features and outcome. Blood 75, 1024-1030 (1990).
32. J. L. Wagner, G. F. Murphy, Pathology and pathogenesis of cutaneous graft-vs.-host disease. In Graft-vs.-Host Disease, J. L. M. Ferrara, K. R. Cooke, H. J. Deeg, Eds. (Marcel Dekker, New York, 2005), pp. 229-255.
33. A. Rauch, M. Bellew, J. Eng, M. Fitzgibbon, T. Holzman, P. Hussey, M. Igra, B. Maclean, C. W. Lin, A. Detter, R. Fang, V. Faca, P. Gafken, H. Zhang, J. Whiteaker, D. States, S. Hanash, A. Paulovich, M. W. McIntosh, Computational Proteomics Analysis System (CPAS): An extensible, opensource analytic system for evaluating and publishing proteomic data and high throughput biological experiments. J. Proteome Res. 5, 112-121 (2006).
34. B. MacLean, J. K. Eng, R. C. Beavis, M. McIntosh, General framework for developing and evaluating database scoring algorithms using the TANDEM search engine. Bioinformatics 22, 2830-2832 (2006).
35. A. Keller, A. I. Nesvizhskii, E. Kolker, R. Aebersold, Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal. Chem. 74, 5383-5392 (2002).
36. A. I. Nesvizhskii, A. Keller, E. Kolker, R. Aebersold, A statistical model for identifying proteins by tandem mass spectrometry. Anal. Chem. 75, 4646-4658 (2003).
37. J. P. Fine, R. J. Gray, A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 94, 496-509 (1999).